Industry in brief | Abbott, Genomma, Recordati
2 August 2021
Abbott, Genomma Lab and Recordati have released financial results.
Industry News - Tag: Recordati
You can read our Premium News Service in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
Recordati recruits Koremans as chief executive
Premium
21 July 2021
Recordati has appointed former Teva executive Rob Koremans as its new chief executive officer with effect from 1 December 2021.
Recordati sets out three-year growth plan
Premium
7 May 2021
Recordati plans to increase sales of its Procto-Glyvenol haemorrhoid treatment by more than a third by 2023 as part of a three-year plan which also includes developing new probiotic food supplements and acquisitions of OTC brands.
Industry in brief | Ipsen, Recordati, Genomma
30 October 2020
France’s Ipsen, Italy’s Recordati and Mexico’s Genomma Labs have recently released financial results.
Fortacin set for centralised OTC switch in Europe
24 July 2020
Recordati’s Fortacin (lidocaine and prilocaine) is set to become the fifth medicine to gain non-prescription status through the European Union’s centralised authorisation procedure.
Industry in brief | Recordati, Adare, Phynova
11 May 2020
Recordati has released financial results, Adare Pharmaceuticals has acquired Orbis Biosciences, and Phynova is raising EUR10 million (USD11 million).
Two centralised OTC switch applications are ongoing
Premium
30 March 2020
Two applications to switch medicines from prescription to non-prescription status through the European Union’s centralised authorisation procedure are still in progress.
Europe to consider two centralised OTC switches
Premium
20 March 2020
Two applications to switch medicines from prescription to non-prescription status through the European Union’s centralised authorisation procedure are set to be discussed by the Committee for Medicinal Products for Human Use (CHMP).